Cell Lysis & Disruption Market is Likely To Touch USD 8.37 Billion by 2028: Grand View Research Inc.

 Cell Lysis & Disruption Market Growth & Trends

The global cell lysis & disruption market size is expected to reach USD 8.37 billion by 2028, registering a CAGR of 9.35% over the forecast period, according to a new report by Grand View Research, Inc. The anticipated revenue growth is attributed to accelerating the adoption of cell lysis and disruption methods during downstream processing to manufacture bio-therapeutics and other animal-based recombinant products. Technological developments in procedures involved in releasing cellular organelles have paved the way for the higher adoption of cell disruption methods.

As retrieval and purification of biopharmaceuticals involve cell disruption, a rise in demand for biopharma would lead to the subsequent growth of the market. In addition, advancements in the field of proteomics, metabolomics, and personalized medicine are expected to fuel progressive changes in this sector. However, the high costs of equipment coupled with the dearth of skilled professionals are expected to restrain revenue generation to a certain extent. The restraint can be addressed as the government organizations are releasing substantial funds to support development in the biotechnology sector.

Enzymatic lysis, owing to higher biological specificity, is likely to register the fastest CAGR over the forecast period. Manufacturers are embracing the trend of providing synthetic enzymes and pre-formulated kits, which can be used for the extraction and purification of proteins, DNA, and RNA. Sonication instruments in the products available are expected to witness lucrative growth due to higher adoption rates as a result of the reliability on these instruments. Factors attributing to this reliability include complete control allowed on parameters and negligible maintenance.

Among the physical methods, the high product yield obtained by sonication of the liquid sample is attributed to the larger revenue share of the ultrasonic homogenization method/technique. Asia Pacific will be the fastest-growing regional market from 2021 to 20285 due to lucrative opportunities offered by emerging nations, which has attracted investments from global firms in the region. Key companies are engaged in new product development and strategic alliances to maintain their market share.

Request a free sample copy or view report summary: Cell Lysis & Disruption Market Report

Cell Lysis & Disruption Market Report Highlights

• A rise in the development of biologics has subsequently led to high demand for better bioprocess solutions
• The advantages offered by reagent-based methods for isolation of biological products is attributive to the largest share of the segment in 2020
• The advantages include an unaltered biological activity of the sample of interest and ideal compatibility with the laboratory reagents
• Therefore, key players have developed different detergent-based solutions and buffers, to provide the best possible results for particular tissue types
• Mammalian cell culture systems have grabbed substantial attention among biopharmaceutical manufacturers, thus leading to higher demand for cell lysis protocols for the same
• Pharmaceutical & biotechnology companies accounted for the largest share as a result of the growing demand for biopharmaceutical products
• Substantial research in the development of nucleic-acid derived products is expected to drive progress in this application in the coming years

Access Press Release@ https://www.grandviewresearch.com/press-release/global-cell-lysis-disruption-market

Cell Lysis & Disruption Market Segmentation

Grand View Research has segmented the global cell lysis & disruption market on the basis of technique, product, cell type, application, end use, and region:

Cell Lysis & Disruption Technique Outlook (Revenue, USD Million, 2018 - 2028)

• Reagent-based
  • Detergent
  • Enzymatic
• Physical Disruption
  • Mechanical Homogenization
  • Ultrasonic Homogenization
  • Pressure Homogenization
  • Temperature Treatments

Cell Lysis & Disruption Product Outlook (Revenue, USD Million, 2018 - 2028)

• Instruments
  • High-pressure Homogenizers
  • Sonicator
  • French Press
  • Microfluidizer
  • Bead Mill
  • Other Instruments
• Reagents & Consumables
  • Enzymes
  • Detergent Solutions
    • Ionic detergent
    • Nonionic detergent
    • Zwitterionic detergent
  • Kits & Reagents

Cell Lysis & Disruption Cell Type Outlook (Revenue, USD Million, 2018 - 2028)

• Mammalian cells
• Bacterial cells
• Yeast/Algae/Fungi
• Plant cells

Cell Lysis & Disruption Application Outlook (Revenue, USD Million, 2018 - 2028)

• Protein Isolation
• Downstream Processing
• Cell Organelle Isolation
• Nucleic Acid Isolation

Cell Lysis & Disruption End-use Outlook (Revenue, USD Million, 2018 - 2028)

• Academic & Research Institutes
• Hospitals & Diagnostic Labs
• Cell Banks
• Pharmaceutical & Biotechnology Companies

Cell Lysis & Disruption Regional Outlook (Revenue, USD Million, 2018 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia

List of Key Players of Cell Lysis & Disruption Market

• Merck KGaA
• Hoffmann-La Roche Ltd.
• Qiagen NV
• Becton Dickinson & Company (BD)
• Danaher Corp.
• Bio-Rad Laboratories, Inc.
• Miltenyi Biotec GmbH
• Claremont BioSolutions, LLC
• Microfluidics International Corp.
• Parr Instrument Company
• BioVision, Inc.
• Covaris, Inc.
• Qsonica LLC

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

U.S. Intravenous Immunoglobulin Market Trends, Company Share, Industry Growth And Future Scope: Grand View Research Inc.

 U.S. Intravenous Immunoglobulin Market Growth & Trends

The U.S. intravenous immunoglobulin market size is expected to reach USD 10.24 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.8% from 2021 to 2028. Robust pipeline, approval and launch of novel products, and increasing government initiatives are expected to be the major factors driving the market.

Robust pipeline and increasing approvals and launches of novel products are anticipated to support the market growth over the forecast period. For instance, in April 2019, U.S.-based ADMA Biologics, Inc. received U.S. FDA approval for its new drug Asceniv. It is an IVIG drug indicated for the treatment of primary humoral immunodeficiency disease. Similarly, in December 2019, CSL Behring announced receiving orphan drug exclusivity for Hizentra from the U.S. FDA to treat Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). In another instance, in February 2021, Biotest AG announced that it was the first in Germany to manufacture an investigational hyper immunoglobulin from plasma protein for the COVID-19 treatment.

Furthermore, increasing initiatives by various government organizations to boost the development of novel products are expected to support market growth over the forecast period. For instance, in January 2018, the National Institutes of Health (NIH) awarded a grant of USD 3 million to the U.S.-based GigaGen Inc. to develop novel recombinant intravenous immunoglobulin for patients with primary immunodeficiency diseases.

However, the manufacturing of IVIG requires a well-developed production facility and high capital investments, thereby leading to the high cost of the final product. Hence, this factor is anticipated to restrain the market growth. In addition, IVIG products undergo stringent regulations pertaining to safety and handling, which is another factor expected to impede the market growth. For instance, in 2018, the U.S. FDA delayed the approval of GC Pharma’s intravenous immunoglobulin product and demanded additional data related to the drug’s manufacturing process.

Request a free sample copy or view report summary: U.S. Intravenous Immunoglobulin Market Report

U.S. Intravenous Immunoglobulin Market Report Highlights

• By application, immunodeficiency diseases dominated the market in 2020 owing to the rising number of cases and the growing adoption of IVIG for the treatment of these diseases
• The multifocal motor neuropathy application segment is expected to register the fastest growth rate over the forecast period due to the high effectivity of IVIG in its treatment
• Based on distribution channel, hospital pharmacy held the largest share in 2020 owing to a large number of hospital pharmacies and the easy availability of products in the hospitals
• Market leaders are involved in the development of new plasma collection centers and other collaborative strategies to expand their geographical reach and widen their product portfolio

Access Press Release@ https://www.grandviewresearch.com/press-release/us-intravenous-immunoglobulin-ivig-market-analysis

U.S. Intravenous Immunoglobulin Market Segmentation

Grand View Research has segmented the U.S. intravenous immunoglobulin market on the basis of application and distribution channel:

U.S. IVIG Application Outlook (Revenue, USD Million, 2016 - 2028)

• Hypogammaglobulinemia
• CIDP
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-barre Syndrome
• Others

U.S. IVIG Distribution Channel Outlook (Revenue, USD Million, 2016 - 2028)

• Hospital Pharmacy
• Specialty Pharmacy
• Others

List of Key Players of U.S. Intravenous Immunoglobulin (IVIG) Market

• Biotest AG
• Octapharma AG
• LFB Biotechnologies S.A.S
• China Biologics Products Holdings, Inc.
• Grifols, S.A.
• Kedrion Biopharma, Inc.
• CSL Behring
• McKesson Corporation
• Takeda Pharmaceutical Company Limited
• Bio Products Laboratory Ltd.
• Pfizer, Inc.
• ADMA Biologics, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Research Antibodies Market Latest Innovations, Drivers and Industry Key Events 2021 – 2028: Grand View Research Inc.

 Research Antibodies Market Growth & Trends

The global research antibodies market size is expected to reach USD 5.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028. Major market drivers include a rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, an increase in neurobiology and stem cell research, availability of technologically advanced products, and strategic collaborations among various key players.

An increase in the usage of research antibodies to develop therapies for various chronic and infectious diseases, including COVID-19, is anticipated to boost the market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid scientists in understanding various aspects of virus pathogenesis entailing further research on antiviral therapies. Growing government funds and initiatives for R&D are anticipated to fuel market growth during the forecast period in the Asia Pacific region. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, a rise in funds invested by pharmaceutical and biotechnology companies to enhance proteomics and genomics research is expected to boost market growth. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. The rise in the number of major players investing in advanced technologies and collaborating with other key players is also anticipated to impact market potential positively in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies. Moreover, the launch of novel antibody structures for the diagnosis of various diseases is also a major factor expected to boost market growth. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry.

Request a free sample copy or view report summary: Research Antibodies Market Report

Research Antibodies Market Report Highlights

• In 2020, primary antibodies held a dominant share in terms of revenue in the product segment owing to greater specificity, therefore, leading to increase adoption in R&D activities        
• Monoclonal antibodiescaptured a substantial share in 2020, as they offer higher sensitivity for the detection of antigens and also showcase efficient staining properties for various applications
• The neurobiology segment is expected to witness exponential growth over the forecast period owing to the increasing prevalence of diseases that have limited treatment options and the rise in R&D activities by biotech companies and academic institutes
• Pharmaceutical and biotechnology companies were dominant in terms of revenue amongst all end-users in 2020, owing to the increased adoption of research antibodies in drug development and discovery
• In 2020, North America accounted for the substantial revenue share which is attributable to the high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories

Access Press Release@ https://www.grandviewresearch.com/press-release/global-research-antibodies-market

Research Antibodies Market Segmentation

Grand View Research has segmented the global research antibodies market on the basis of product, type, technology, source, application, end-use, and region:

Research Antibodies Product Outlook (Revenue, USD Million, 2018 - 2028)

• Primary
• Secondary

Research Antibodies Type Outlook (Revenue, USD Million, 2018 - 2028)

• Monoclonal Antibodies
• Polyclonal Antibodies

Research Antibodies Technology Outlook (Revenue, USD Million, 2018 - 2028)

• Immunohistochemistry
• Immunofluorescence
• Western Blotting
• Flow Cytometry
• Immunoprecipitation
• ELISA
• Other Technologies

Research Antibodies Source Outlook (Revenue, USD Million, 2018 - 2028)

• Mouse
• Rabbit
• Goat
• Other Sources

Research Antibodies Application Outlook (Revenue, USD Million, 2018 - 2028)

• Infectious Diseases
• Immunology
• Oncology
• Stem Cells
• Neurobiology
• Other Applications

Research Antibodies End-use Outlook (Revenue, USD Million, 2018 - 2028)

• Academic & Research Institutes
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies

Research Antibodies Regional Outlook (Revenue, USD Million, 2018 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • China
  • Australia
  • India
  • Japan
  • Singapore
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Research Antibodies Market

• Abcam Plc
• Bio-rad Laboratories
• Becton Dickinson & Company
• Merck Millipore
• Lonza Group
• Thermo Fisher Scientific, Inc.
• Cell Signalling Technology, Inc.
• Hoffmann La Roche Ltd.
• Agilent Technologies
• Perkinelmer, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Medical Billing Outsourcing Market to Witness Soaring Growth During the Forecast Period: Grand View Research Inc.

 

Medical Billing Outsourcing Market Growth & Trends

The global medical billing outsourcing market size is projected to reach USD 25.9 billion by 2028, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.66% from 2021 to 2028. A large amount of clinical code representation for diagnosis and treatment coupled with the presence of multiple payers renders medical billing an intricate part of any clinical practice, posing significant challenges. Currently, the healthcare system is witnessing a subsequent rise in the outsourcing of clinical billing services by hospitals and physicians due to obligatory implementation of complex ICD-11 coding systems, increasing healthcare costs, and a federal mandate to implement Electronic Medical Records (EMR) to maintain reimbursement levels.

The COVID-19 pandemic has negatively affected the market. Though, the healthcare industry was trailing in embracing innovative and digital technologies to improve healthcare. The COVID-19 scenario has put an enormous burden on healthcare providers/organizations to become accustomed to the change. The recovery from the financial impact of the coronavirus pandemic could take a long time. Thus, players operating in the market need to create new policies/strategies powered by telemedicine solutions and patient-centric collections to rise above the challenges of COVID-19.   

Furthermore, clinics/physician offices are gradually outsourcing their revenue management to cut unnecessary costs and prevent the burden of managing an administrative team to ensure effective handling of in-house billing functions. In addition, multispecialty healthcare groups are implementing consolidation requiring EHR integration and building large healthcare networks. This integration creates a need for revenue cycle management (RCM), which, in turn, demands additional expertise and trained personnel to manage the same. Thus, the consolidation of large healthcare practices is also expected to be one of the factors fueling the market growth.

Request a free sample copy or view report summary: Medical Billing Outsourcing Market Report

Medical Billing Outsourcing Market Report Highlights

• The outsourced segment accounted for the largest revenue share in 2020 and is expected to witness a high CAGR attributed to the rising preference of hospitals, physician office, and startups opting for outsourced medical billing services for hassle-free claim management at low cost
• The front-end services segment led the market in 2020. However, the middle-end services segment is expected to register the highest CAGR over the forecast period due to the growing demand for Revenue Cycle Management (RCM) services offering Electronic Health Records (EHR) software
• Hospitals, possessing higher claim volumes, accounted for the largest revenue share in the market in 2020 and is estimated to maintain the dominance even during the forecast years
• North America held the largest revenue share in 2020. It is projected to expand further as U.S. has witnessed a change in the healthcare system with the introduction of ICD-11 coding in 2019 and pressure from the government to incorporate the Electronic Medical Record (EMR) management system
• Medical billing and Revenue Cycle Management (RCM) companies such as Athenahealth, are offering successful implementation of EMR at the practice level and are expected to transform the market

Access Press Release@ https://www.grandviewresearch.com/press-release/global-medical-billing-outsourcing-market

Medical Billing Outsourcing Market Segmentation

Grand View Research has segmented the global medical billing outsourcing market on the basis of component, service, end-use, and region:

Medical Billing Outsourcing Component Outlook (Revenue, USD Million, 2016 - 2028)

• In-house
• Outsourced

Medical Billing Outsourcing Service Outlook (Revenue, USD Million, 2016 - 2028)

• Front End
• Middle End
• Back End

Medical Billing Outsourcing End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospital
• Physician Office
• Others

Medical Billing Outsourcing Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • Spain
  • France
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia

List of Key Players of Medical Billing Outsourcing Market

• R1 RCM, Inc.
• Cerner Corporation
• Allscripts Healthcare Solutions, Inc.
• Experian Information Solutions, Inc.
• eClinicalWorks
• GE Healthcare
• Genpact
• HCL Technologies Limited
• Kareo, Inc.
• McKesson Corporation
• Quest Diagnostics
• Athenahealth Inc.
• The SSI Group, LLC.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Pulmonary Arterial Hypertension Market is Likely To Touch USD 7.7 Billion by 2028: Grand View Research Inc.

 Pulmonary Arterial Hypertension Market Growth & Trends

The global pulmonary arterial hypertension market size is expected to reach USD 7.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.9% from 2021 to 2028. Increasing prevalence rates of pulmonary arterial hypertension (PAH) and government support for the development of orphan drugs are fueling the market growth.

The COVID-19 pandemic did not have much impact on the PAH market due to the normal demand for PAH drugs by the patients. All the market players reported positive growth rates in their year-on-year revenues from 2019 to 2020. However, the supply chains were disrupted to a certain level due to lockdowns in many nations globally. Overall, the impact was neutralized due to the continuous demand for drugs.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of this disorder is intensifying due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions.

The existence of a large geriatric population having lower levels of immunity is prone to PAH and associated diseases is a high impact-rendering factor for the growth of the PAH market over the forecast period. Though the beginning age for PAH is 45 years, it is often observed to occur in a population over 60 years of age.

Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth. These are the two most vital acts that promote the ethical usage and distribution of orphan drugs. The development of orphan drugs is promoted by the National Organization of Rare Disorders and has a smaller market share.

Robust drug pipeline and new product combination awaiting approval or launch are anticipated to heighten the market competitiveness over the forecast period. In December 2020, Acceleron Pharma received orphan drug designation for Sotatercept from the European Commission and is available for commercial use in the European markets.

Request a free sample copy or view report summary: Pulmonary Arterial Hypertension Market Report

Pulmonary Arterial Hypertension Market Report Highlights

• By drug class, prostacyclin and prostacyclin analogs are projected to witness lucrative growth over the forecast period. The sales of these drugs are anticipated to grow sharply in the future, primarily due to the growth expected in oral prostacyclin agents
• North America dominated the PAH market with over 55.0% share in 2020. This is attributed to its supportive infrastructure for the development and distribution of high-quality therapies. In addition, the availability of reimbursement on PAH therapies support the market growth
• Asia Pacific is anticipated to expand at the fastest CAGR of 5.9% over the forecast period due to its large population base, rapid economic developments, and improving healthcare systems. Besides, the high burden of diseases such as HIV, which are responsible for the development of PAH, foster the growth of this regional market
• The market is consolidated and competitive. Players enjoy the benefit of high entry barriers to other firms due to the high price interdependency

Access Press Release@ https://www.grandviewresearch.com/press-release/global-pulmonary-arterial-hypertension-pah-market-size-report

Pulmonary Arterial Hypertension Market Segmentation

Grand View Research has segmented the global pulmonary arterial hypertension market based on drug class and region:

Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2016 - 2028)

• Prostacyclin and Prostacyclin Analogs
• Soluble Guanylate Cyclase (SGC) Stimulators
• Endothelin Receptor Antagonist (ERA)
• Phosphodiesterase 5 (PDE-5)

Pulmonary Arterial Hypertension Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Pulmonary Arterial Hypertension Market

• Johnson & Johnson Services, Inc.
• United Therapeutics Corporation
• Pfizer, Inc.
• Acceleron Pharma, Inc.
• Gilead Sciences, Inc.
• Bayer AG
• GlaxoSmithKline Plc. (GSK)

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Long Term Care Market Revenue is Expected to Reach USD 1.7 Trillion by 2028: Grand View Research Inc.

 Long Term Care Market Growth & Trends

The global long term care market size is expected to reach USD 1.7 trillion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.1% from 2021 to 2028. The market is expected to grow primarily owing to the rising prevalence of target diseases, especially Alzheimer’s and dementia, among the aging population. In addition to this, increasing awareness about different long term care (LTC) facilities and the increasing medical coverage for home healthcare are likely to benefit the market growth.

According to World Population Prospects 2020, the global population aged 65 years and above was 703 million in 2020. The number of elderly people is projected to double by 2050 to reach 1.5 billion. The global share of the elderly population increased to 9% in 2020 from 6% in 1990 and is expected to rise further to 16% by 2050 with one in every six people in the world being over 65 years of age. It is expected that people turning 65 years are more likely to take some type of long term care services in the years to come. There has also been a shift towards in-home care from hospitals.

Developing economies make for lucrative markers as far as home healthcare is concerned. India, for instance, has many home healthcare startups such as Health Care at Home, Zoctr, Vatsalya, Zozz, Life Circle Health Services, Healers at Home, and the Nightingales, a factor that has worked in its favor. In India, Portea is one of the key market leaders in in-home healthcare. In November 2017, Portea raised USD 26.0 million in Series C funding for better home healthcare facilities.

Asia Pacific is expected to witness significant growth over the forecast period owing to the increasing rate of chronic diseases, the increasing disposable income, and the decreasing working population. For instance, in China, the one-child policy has eventually decreased the working population as compared to the older population. Industry players are continuously investing in expanding and revamping existing facilities. For instance, in February 2020, Genesis HealthCare underwent a real estate partnership with Next Healthcare Capital. The deal involved 15 skilled nursing facilities previously leased from Welltower Inc.

Request a free sample copy or view report summary: Long Term Care Market Report

Long Term Care Market Report Highlights

• The pandemic has created significant pressure on the entire healthcare system, but the most tragic impact is on the long term care facilities for both the younger and older generations in residential care programs
• In terms of service, nursing care held the largest share in 2020 owing to the presence of a large number of facilities offering nursing care, medical supervision, and round-the-clock assistance
• The home healthcare segment emerged as the second-largest service segment in 2020 owing to the increasing awareness regarding such facilities, cost savings offered by them as compared to hospital stays or nursing homes, and proactive health monitoring
• The hospice service segment is expected to witness the fastest growth over the forecast period owing to the increasing incidence rate of Alzheimer's and dementia and an increase in post-hospital care. Moreover, the coverage offered by both Medicaid and private insurers has relieved residents from out-of-pocket payments that have to be borne by them
• North America dominated the market in 2020. This is majorly attributed to the advanced medical infrastructure, awareness about the advantages of home health services, rising geriatric population, and government support. Around 13% of the people in the U.S. are 65 years or above and it is expected that by 2050, one in six Americans would be at least 65 years of age

Access Press Release@ https://www.grandviewresearch.com/press-release/global-long-term-care-market

Long Term Care Market Segmentation

Grand View Research has segmented the global long term care market based on service and region:

Long Term Care Service Outlook (Revenue, USD Billion, 2016 - 2028)

• Home Health Care
• Hospice
• Nursing Care
• Assisted Living Facilities
• Others

Long Term Care Regional Outlook (Revenue, USD Billion, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa

List of Key Players of Long Term Care Market

• Brookdale Senior Living, Inc.
• Sunrise Carlisle, LP
• Atria Senior Living Group
• Extendicare, Inc.
• Capital Senior Living
• Diversicare Healthcare Services Inc.
• Kindred Healthcare, Inc.
• Genesis Healthcare Corp.
• Senior Care Centers of America
• Home Instead Senior Care, Inc.
• Amedisys, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Continuous Glucose Monitoring Device Market Industry Analysis , Opportunity Assessment And Forecast Till 2028: Grand View Research Inc.

 Continuous Glucose Monitoring Device Market Growth & Trends

The global continuous glucose monitoring device market size is expected to reach USD 10.36 billion by 2028, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 10.1% from 2021 to 2028. Growing cases of diabetes and introduction of novel and advanced diabetes care devices are the major factors driving the market growth. Continuous glucose monitoring (CGM) devices provide an efficient method to measure body glucose levels in real time. Data recorded by these devices is transmitted through a wireless network to receivers; this helps keep a track of glucose levels over a designated period.

These devices also help manage diabetes while reducing individual insulin dosages. Integrated software within these devices provides users with insights about food consumption, medication, physical activity, and illnesses. Thus, an increasing number of diabetic patients are using these devices to manage and treat diabetes, which, in turn, is accelerating market growth. With the advent of digital therapeutics, a rising number of continuous glucose monitoring devices are being incorporated with apps and software to help patients with diabetes mellitus. Rise in the number of diabetes mellitus has been contributing toward continuous glucose monitoring (CGM) systems market growth.

Request a free sample copy or view report summary: Continuous Glucose Monitoring Device Market Report

Continuous Glucose Monitoring Device Market Report Highlights

• Growing cases of diabetes is anticipated to propel market growth, with increasing number of patients opting for simplified CGM devices
• CGM devices provide analysis of blood glucose levels from the tissue fluid at regular intervals of time, which is also driving their demand
• Sensors was the largest component type segment and is anticipated to maintain its dominance owing to their integral nature in these devices
• Asia Pacific is the leading regional continuous glucose monitoring device market, with Japan, China, and India on the forefront
• North America led the global market in the past owing to wide usage of CGM devices as a result of higher number of target patients in the region
• The European region followed the North American closely in terms of market revenue due to rise in the adoption of these devices in key countries such as U.K., Germany, France, Italy, and Spain
• Some of the key companies present in the market are Pfizer Inc.; Baxter International, Inc.; Abbott Laboratories; Medtronic PLC; Animas Corporation; and Novo Nordisk A/S.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-continuous-glucose-monitoring-cgm-devices-market

Continuous Glucose Monitoring Device Market Segmentation

Grand View Research has segmented the global continuous glucose monitoring device market on the basis of component, end use, and region:

CGM Devices Component Outlook (Revenue, USD Million, 2016 - 2028)

• Transmitters
• Sensors
• Receivers

CGM Devices End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals
• Home Care
• Others

CGM Devices Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
• Asia Pacific
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Saudi Arabia

List of Key Players of Continuous Glucose Monitoring Device Market

• Medtronic
• Dexcom, Inc.
• Hoffmann-La Roche Ltd.
• Abbott
• Novo Nordisk A/S
• Ypsomed
• GlySens, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Expansion of Scanning Electron Microscopes Market During 2021 – 2028 to Gain Robust Traction: Grand View Research Inc.

 Scanning Electron Microscopes Market Growth & Trends

The global scanning electron microscopes market size is expected to reach USD 6.5 billion by 2028, registering a CAGR of 8.52% over the forecast period, according to a new report by Grand View Research, Inc. Rising demand for nanotechnology-based research and growing R&D innovation in application areas are anticipated to serve as key growth drivers. Rapid growth witnessed in application areas, such as semiconductors, automobiles, pharmaceuticals, and nanotechnology, globally is among the key factors responsible for the significant growth of the SEM market.

Technological advancements in SEM improves the quality control procedures of research laboratories in a wide range of industries, such as semiconductors, automobiles, and pharmaceutical manufacturing. Scanning electron microscopy plays a critical role in the imaging and elemental analysis of products. However, the advanced SEMs offer advantages, such as rapid analysis, compact size, and efficient results with higher resolution and 3D imaging. Furthermore, the COVID-19 pandemic is expected to increase the sale of SEMs.

Due to the growing prevalence of communicable diseases, the market is expected to observe substantial growth over the coming years. Market participants are entering into partnerships and collaborations to prove their technical capabilities. For instance, in November 2020, Thermo Fisher Scientific Inc. partnered with Nanoimaging Services (NIS)-a provider of Transmission Electron Microscopy (TEM) services. The partnership helped Thermo Fisher Scientific Inc. obtain better accessibility to NIS’s cryoelectron microscopy (cryoEM) technology for pharmaceutical applications and biotechnology.

Request a free sample copy or view report summary: Scanning Electron Microscopes Market Report

Scanning Electron Microscopes Market Report Highlights

• Application of SEM in life science is expected to account for a share of 24.77% by 2028 owing to the rising prevalence of chronic diseases leading to increased R&D expenditure and demand for digital microscopes in the fields of life sciences and medicine
• Asia Pacific is expected to witness the fastest CAGR from 2021 to 2028 due to the presence of world-class manufacturers in this region and increasing usage of SEM for elemental analysis and imaging
• Growing demand for advanced SEMs for the range of material research is expected to boost the market growth in Latin America, which is expected to grow at a CAGR of 8.6% over the forecast period
• Mergers & collaborations and product developments are the key strategies being undertaken by the market players
• For instance, in January 2020, ZEISS and RIKEN Innovation entered into a partnership agreement. The partnership was aimed at expediting bioengineering innovations and bringing change in healthcare

Access Press Release@ https://www.grandviewresearch.com/press-release/global-scanning-electron-microscope-market

Scanning Electron Microscopes Market Segmentation

Grand View Research has segmented the global scanning electron microscopes market on the basis of application and region:

Scanning Electron Microscope Application Outlook (Revenue, USD Million, 2016 - 2028)

• Material Science
• Nanotechnology
• Life Science
• Semiconductors
• Other Applications

Scanning Electron Microscope Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa (MEA)
  • South Africa

List of Key Players of Scanning Electron Microscopes Market

• Bruker Corp.
• Danish Micro Engineering (DME)
• Thermo Fisher Scientific
• Hitachi High Technologies Corp.
• JEOL Ltd.
• Leica Microsystems
• Nanoscience Instruments, Inc.
• Nikon Corp.
• Olympus Corp.
• Carl Zeiss

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Intravenous Iron Drugs Market to Reflect Robust Expansion During 2021-2028: Grand View Research Inc.

 Intravenous Iron Drugs Market Growth & Trends

The global intravenous iron drugs market size is expected to reach USD 4.2 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.5% from 2021 to 2028. The introduction of novel formulations with expanded indications, increasing R&D activities, and rising awareness for diagnosis and treatment of anemia is expected to propel market demand over the forecast period.

The increase in the prevalence of chronic diseases, such as chronic kidney disease, cancer, inflammatory bowel diseases, diabetes, and acute and chronic infections, has been a major market driver facilitating a significant demand for intravenous iron drugs. According to the Globol can estimates, in 2020, around 19,292,789 new cases of cancer were diagnosed globally, which lead to around 9,958,133 deaths in the same year. According to the data published by the CDC, in 2019, an estimated 15% of U.S. adults, or around 37 million adults, are suffering from chronic kidney disease (CKD). The same source also stated that diabetes and high blood pressure are the major causes of CKD in adults, and CKD is more common in people aged 65 years or older. The rise in the incidence of chronic kidney disease globally, due to unhealthy lifestyles, has been a major growth factor for the market.

Furthermore, increasing approval and indication expansion of iron drugs in key markets has significantly supported market growth. In February 2021, Pharmacosmos announced that the National Medical Products Administration (NMPA) approved Monofer injection 100 mg/mL in China. Also, in February 2018, the company announced that the U.S. FDA approved Supplemental New Drug Application (sNDA) for Feraheme (ferumoxytol injection). The FDA approved the use of Feraheme by an eligible adult suffering from Iron Deficiency Anemia (IDA).

Request a free sample copy or view report summary: Intravenous Iron Drugs Market Report

Intravenous Iron Drugs Market Report Highlights

• Effects of the ongoing pandemic have also shown an estimated 14.0% to 30.0% kidney function loss among COVID-19 patients. Thus, increased the demand for iron drugs for the management of kidney disease-induced anemia in COVID-19 patients
• The Ferric Carboxymaltose segment accounted for the largest revenue share in 2020. Its high share is attributed to the high revenue generation of Ferinject/Injectafer in key markets
• The Chronic Kidney Disease (CKD) segment dominated the market in 2020. Its leading share is attributed to the increasing prevalence of CKD and the high incidence of IDA among CKD patients
• Key players are undertaking extensive strategic initiatives in the market, such as mergers and acquisitions, new product developments, and regional expansion, to address the growing demand
• North America dominated the market with the largest revenue share in 2020. The presence of major players and favorable reimbursement scenarios are facilitating the dominance of this region during the study period
• Asia Pacific is projected to witness a lucrative CAGR owing to the high prevalence of IDA in emerging economies

Access Press Release@ https://www.grandviewresearch.com/press-release/global-intravenous-iron-drugs-market

Intravenous Iron Drugs Market Segmentation

Grand View Research has segmented the global intravenous iron drugs market on the basis of product, application, and region:

Intravenous Iron Drugs Product Outlook (Revenue, USD Million, 2016 - 2028)

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Others

Intravenous Iron Drugs Application Outlook (Revenue, USD Million, 2016 - 2028)

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Others

Intravenous Iron Drugs Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • Spain
  • France
  • Italy
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Intravenous Iron Drugs Market

• Vifor Pharma Management Ltd.
• AMAG Pharmaceuticals
• Daiichi Sankyo Company, Ltd. (American Regent. Inc.)
• Sanofi S.A.
• Pharmacosmos A/S
• Shield Therapeutics Plc
• AbbVie Inc. (Allergan Plc)

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Global Market For Circulating Tumor Cells Industry to Witness Tremendous Growth and Expansion by 2028

 

Circulating Tumor Cells Market Growth & Trends

The global circulating tumor cells market size is expected to reach USD 18.3 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.7% from 2021 to 2027. Many potential applications of CTCs in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products Research organizations are engaged in endeavors aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed.

Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

The limited applicability of these cells in rare cancers has hampered the revenue growth up to a certain extent. For instance, there is negligible evidence for the characterization of CTCs for sarcoma. Conversely, several methods are being investigated for the isolation of these cells, such as methods based on epithelial antigen-targeted antibodies, which are anticipated to help overcome these challenges in the coming years.

Request a free sample copy or view report summary: Circulating Tumor Cells Market Report

Circulating Tumor Cells Market Report Highlights

• The CTC detection and enrichment methods accounted for the largest revenue share owing to the presence of wide availability of products for CTC enrichment and isolation
• Moreover, high penetration in terms of usage of products offered under this segment has driven the segment share
• The growing application of nanomaterials in cancer management is anticipated to drive revenue for direct detection methods in the coming years
• The devices and systems segment dominated the market in terms of revenue share in 2020 over its counterpart segments including kits and reagents and blood collection tubes
• The presence of high-throughput automated systems coupled with the availability of a substantial number of systems to carry out detection of tumor cells has contributed to a large revenue share
• CTC analysis has major applications in research settings, including investigational research, drug developments, and biomarker studies. This has resulted in a segment’s large revenue share
• Currently, whole blood specimens are the key source of CTCs, thus accounting for the largest share in 2020
• Low use of bone marrow-derived cells in clinical settings has contributed to a smaller revenue share of this segment
• Other sources include CSF, spinal fluids, urine, and pleural effusion
• Easy availability of biological specimens, such as urine, is likely to accelerate adoption under this segment
• The market is fragmented in nature with the presence of well-established players, along with medium to small-sized players

Access Press Release@ https://www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market

Circulating Tumor Cells Market Segmentation

Grand View Research has segmented the global Circulating Tumor Cells market on the basis of technology, application, product, specimen, and region:

CTCs Technology Outlook (Revenue, USD Million, 2018 - 2027)

• CTC Detection & Enrichment Methods
  • Immunocapture (Label-based)
    • Positive Selection
    • Negative Selection
  • Size-based Separation (Label-free)
    • Membrane-based
    • Microfluidic-based
  • Density-based Separation (Label-free)
  • Combined Methods (Label-free)
• CTC Direct Detection Methods
  • SERS
  • Microscopy
  • Others
• CTC Analysis

CTCs Application Outlook (Revenue, USD Million, 2018 - 2027)

• Clinical/ Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell & Tumorogenesis Research
  • Drug/Therapy Development

CTCs Product Outlook (Revenue, USD Million, 2018 - 2027)

• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

CTCs Specimen Outlook (Revenue, USD Million, 2018 - 2027)

• Blood
• Bone Marrow
• Other Body Fluids

CTCs Regional Outlook (Revenue, USD Million, 2018 - 2027)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE

List of Key Players of Circulating Tumor Cells (CTCs) Market

• QIAGEN
• Bio-Techne Corporation
• Precision for Medicine
• AVIVA Biosciences
• BIOCEPT, Inc.
• BioCEP Ltd.
• Fluxion Biosciences, Inc.
• Greiner Bio One International GmbH
• Ikonisys Inc.
• Miltenyi Biotec
• IVDiagnostics
• BioFluidica
• Canopus Bioscience Ltd.
• Biolidics Limited
• Creativ MicroTech, Inc.
• LungLife AI, Inc.
• Epic Sciences
• Rarecells Diagnostics
• ScreenCell
• Menarini Silicon Biosystems
• LineaRx, Inc. (Vitatex, Inc.)
• Sysmex Corporation
• STEMCELL Technologies, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.